Early Development Asset Lead

Overview

In this role you lead one or more Early Development Asset Teams to shape the strategy and execution of early-stage therapeutic assets. You own integrated development plans spanning preclinical to regulatory activities, ensuring alignment with portfolio priorities and evidence-based decision-making. As scientific champion, you articulate project goals and translational rationale to internal and external stakeholders. You may represent Early Development in due diligence and governance discussions, driving rigorous, cross-functional progress.

Responsibilities

• Leads one or more Early Development Asset Teams
• Owns integrated program strategy across preclinical, translational, clinical, diagnostic, and regulatory activities
• Develops and maintains integrated asset strategy including target product profile, indication strategy, and evidence requirements
• Ensures plans deliver against Therapeutic Area strategy and portfolio priorities with evidence-based rationale for stage-gate decisions
• Integrates input from critical functions to balance scientific risk, timelines, cost, and clinical proof-of-concept potential
• Ensures adequate resources and leads risk mitigation strategies
• Presents plans, data, risks, options, and recommendations to governance bodies
• Builds high-functioning cross-functional teams and maintains a collaborative, inclusive environment
• Serves as scientific champion articulating translational hypotheses and clinical strategy
• Contributes to due diligence for in-licensing opportunities and may coordinate findings for governance

Key requirements

• PhD, MD, or PharmD with 10-15 years of multidisciplinary drug development experience
• Deep oncology understanding; immuno-oncology and/or ADCs desirable
• Cross-functional drug development experience across nonclinical, translational, regulatory, or clinical areas
• Experience with small molecules, biologics, and novel modalities preferred
• Translational strategy experience including biomarker and precision medicine in early trials
• Experience with regulatory filings (IND/CTA) and health authority interactions
• Strong leadership in matrix environments with cross-regional collaboration
• Excellent written and spoken English; French or another European language is an advantage

• Strong leadership in cross-functional, matrix environments
• Excellent communication and stakeholder management
• Strategic thinking with evidence-based decision making
• Integrated development strategy (preclinical to regulatory)
• Translational and biomarker strategy
• Regulatory filings (IND/CTA)

…